Exhibit 5.1
| | |
![LOGO](https://capedge.com/proxy/S-8/0001193125-20-153199/g875477snap0003.jpg)
| | Mayer Brown International LLP 201 Bishopsgate London EC2M 3AF United Kingdom T: +44 20 3130 3000 F: +44 20 3130 3001 DX: 556 London and City mayerbrown.com |
27 May 2020
GW Pharmaceuticals plc
Sovereign House
Vision Park, Chivers Way
Histon
Cambridge
CB24 9BZ
Our ref: 20456/13428626
Dear Sir
Registration Statement on FormS-8
We have acted for GW Pharmaceuticals plc, a public limited company incorporated under the laws of England and Wales (the“Company”), as its legal advisers in England in connection with the registration statement on FormS-8 (the“Registration Statement”) to be filed on or about 27 May 2020 by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the“Securities Act”), and the rules and regulations promulgated thereunder (the“Rules”), relating to the registration of an aggregate of 22,200,000 ordinary shares of £0.001 each in the Company (the“Shares”). The Shares are issuable under the GW Pharmaceuticals plc 2020 Long-Term Incentive Plan (as amended on 19 May 2020 and approved by shareholders on 26 May 2020) (the“Plan”).
We understand that the ordinary shares of £0.001 each in the capital of the Company are not, and are not intended to be, admitted to trading on any market or exchange, or otherwise listed, in the United Kingdom.
In connection with the Registration Statement, we have been asked to provide an opinion on certain matters, as set out below. We have taken instructions in relation to this opinion solely from the Company.
2. | Examination and enquiries |
| (a) | For the purpose of giving this opinion, we have examined: |
| (i) | a copy of the Registration Statement (excluding its exhibits and any documents incorporated by reference into the Registration Statement); and |
This is a legal communication, not a financial communication. Neither this nor any other communication from this firm is intended
to be, or should be construed as, an invitation or inducement (direct or indirect) to any person to engage in investment activity.
Mayer Brown International LLP is a limited liability partnership (registered in England and Wales number OC303359), which is authorised and regulated by the Solicitors Regulation Authority with SRA number 369822. Mayer Brown is a global services provider comprising an association of legal practices that are separate entities including Mayer Brown LLP (Illinois, USA), Mayer Brown International LLP (England), Mayer Brown (a Hong Kong partnership) and Tauil & Chequer Advogados (a Brazilian partnership).
We use the term “partner” to refer to a member of Mayer Brown International LLP, or an employee or consultant who is a lawyer with equivalent standing and qualifications and to a partner of or lawyer with equivalent status in another Mayer Brown entity. A list of the names of members of Mayer Brown International LLP and their respective professional qualifications may be inspected at our registered office, 201 Bishopsgate, London EC2M 3AF, England or on www.mayerbrown.com.